PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11216879-0	2001	Comparative effect of danazol and a GnRH agonist on monocyte chemotactic protein-1 expression by endometriotic cells.	Danazol	22-29	C-C motif chemokine ligand 2	Homo sapiens	52-82	
11216879-6	2001	RESULTS: Our results show that danazol concentrations (10(-7) -10(-5) M), taking into account the therapeutic levels found in the plasma of treated patients, inhibited MCP-1 protein and mRNA steady-state levels in endometriotic cells, whereas buserelin acetate (0.1-10 ng/mL), a GnRH agonist, had no significant effect.	Danazol	31-38	C-C motif chemokine ligand 2	Homo sapiens	168-173	
11216879-8	2001	CONCLUSIONS: These results put into prominence the capability of danazol to directly inhibit the expression of a potent monocyte chemotactic and activating factor by ectopic endometrial cells shedding more light on the mechanisms underlying the clinical effects of hormonal therapeutic agents used in the treatment of endometriosis.	Danazol	65-72	C-C motif chemokine ligand 2	Homo sapiens	120-162	
11056242-1	2000	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as danazol and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells.	Danazol	101-108	C-C motif chemokine ligand 2	Homo sapiens	161-191	
11056242-1	2000	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as danazol and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells.	Danazol	101-108	C-C motif chemokine ligand 2	Homo sapiens	193-198